Featured in Precision Medicine Online
Interview by Catherine Shaffer
Helio Genomics, a company that has already used artificial intelligence tools to develop a liver cancer test, has ambitions to develop other precise cancer diagnostics by applying deep learning models and generative AI.
In Genome Medicine in January, Helio Genomics, formerly known as Helio Health, published results from a study assessing the effectiveness of an AI-driven platform dubbed MESA, which stands for multimodal epigenetic sequencing analysis, as a colorectal cancer screening tool. The platform combines cell-free DNA (cfDNA) methylation analysis with machine learning methods to identify biomarker signatures that can detect cancer in its earliest stages. MESA is designed to detect cancer early by incorporating four parameters: cfDNA methylation, nucleosome occupancy, nucleosome fuzziness — a measure of delocalization of the nucleosome — and a windowed protection score for regions surrounding gene promoters and polyadenylation sites.
Read the full interview at Precision Medicine Online